Executive readout · one minute
Call research workspace
Read the call alongside every captured source. Audio, transcript, slides and SEC filings stay in one workspace.
NEO
$15.94
-2.75%
NEO · Neogenomics Inc
$15.94
-0.45 (-2.75%)
At close · Aug 14
Market Cap
$2.08B
Shares
130.21M
All earnings calls
Earnings call · FY2025 Q4
Neogenomics Inc Q4 FY2025 Earnings Call
Neogenomics Inc Q4 FY2025 Earnings Call
Forward guidance
6 guided metrics
Management's latest ranges and targets are included below.
Research coverage
3 live sources
Switch sources without leaving this page or losing your listening position.
Revenue · derived Q4
$190.17M
+10.6% YoY
Gross margin · derived Q4
43.8%
-1.1 pp YoY
Net income · derived Q4
-$9.88M
Research materials
Open the source you need; every reader stays inside this workspace.
Forward guidance
From the 8-K filed Feb 17, 2026.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
Consolidated revenue
table
FY 2026
|
$793M – $801M | — | |
|
Net loss
table
FY 2026
|
$-63M – $-50M | GAAP | |
|
Adjusted EBITDA
table
FY 2026
|
$55M – $57M | Non-GAAP | |
|
Net loss per diluted share
table
FY 2026
|
$-0.48 – $-0.38 | GAAP | |
|
Adjusted diluted EPS
table
FY 2026
|
$0.16 – $0.21 | Non-GAAP | |
|
Adjusted net income
table
FY 2026
|
$21M – $27M | Non-GAAP |
Listen and read together
Transcript
The spoken word highlights as audio plays. Select any word to seek to that moment.
1:04:11
Audio
Audio replay
A speaker-labelled transcript is not available for this event yet.
SEC filing · Item 2.02
8-K earnings release
Filed Feb 17, 2026 · complete as-filed document
SEC periodic report
10-K report
Filed Feb 17, 2026 · complete as-filed document